J. Kærn

5.0k total citations
111 papers, 3.5k citations indexed

About

J. Kærn is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, J. Kærn has authored 111 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Reproductive Medicine, 30 papers in Oncology and 27 papers in Surgery. Recurrent topics in J. Kærn's work include Ovarian cancer diagnosis and treatment (77 papers), Endometrial and Cervical Cancer Treatments (25 papers) and Intraperitoneal and Appendiceal Malignancies (18 papers). J. Kærn is often cited by papers focused on Ovarian cancer diagnosis and treatment (77 papers), Endometrial and Cervical Cancer Treatments (25 papers) and Intraperitoneal and Appendiceal Malignancies (18 papers). J. Kærn collaborates with scholars based in Norway, Australia and United Kingdom. J. Kærn's co-authors include Claes G. Tropé, Vera M. Abeler, Claes G. Tropé, Ignace Vergote, Ben Davidson, Gunnar B. Kristensen, Erik O. Pettersen, Torbjørn Paulsen, Claes Tropé and Christian Marth and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Oncology.

In The Last Decade

J. Kærn

108 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Kærn Norway	36	2.3k	1.2k	1.1k	809	640	111	3.5k
Catherine Lhommé France	33	2.0k 0.9×	1.0k 0.9×	955 0.9×	949 1.2×	1.3k 2.0×	119	4.2k
Carmen Tornos United States	38	2.0k 0.9×	1.9k 1.6×	621 0.6×	916 1.1×	950 1.5×	91	4.4k
Ronald P. Zweemer Netherlands	27	1.6k 0.7×	1.1k 1.0×	508 0.5×	703 0.9×	438 0.7×	109	2.9k
Satoru Sagae Japan	28	1.3k 0.6×	982 0.8×	529 0.5×	731 0.9×	900 1.4×	75	3.0k
Anna Yemelyanova United States	25	1.2k 0.5×	796 0.7×	627 0.6×	492 0.6×	345 0.5×	55	2.2k
Raji Ganesan United Kingdom	30	1.2k 0.5×	1.6k 1.3×	715 0.7×	428 0.5×	547 0.9×	112	3.1k
Pamela J. Paley United States	26	1.3k 0.6×	903 0.8×	542 0.5×	392 0.5×	466 0.7×	41	2.2k
Harrison Ball United States	22	1.6k 0.7×	994 0.8×	1.1k 1.0×	534 0.7×	280 0.4×	47	2.4k
C. Lhommé France	30	1.4k 0.6×	1.2k 1.0×	940 0.9×	677 0.8×	410 0.6×	147	2.8k
Prafull Ghatage Canada	29	1.3k 0.6×	887 0.7×	687 0.6×	855 1.1×	845 1.3×	110	2.9k

Countries citing papers authored by J. Kærn

Since Specialization

Citations

This map shows the geographic impact of J. Kærn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Kærn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Kærn more than expected).

Fields of papers citing papers by J. Kærn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Kærn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Kærn. The network helps show where J. Kærn may publish in the future.

Co-authorship network of co-authors of J. Kærn

This figure shows the co-authorship network connecting the top 25 collaborators of J. Kærn. A scholar is included among the top collaborators of J. Kærn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Kærn. J. Kærn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Langseth, Hilde, et al.. (2018). Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum‐sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry‐based study. Acta Obstetricia Et Gynecologica Scandinavica. 97(8). 956–965. 6 indexed citations

Sorio, Roberto, C. Roemer-Bécuwe, Felix Hilpert, et al.. (2016). Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecologic Oncology. 144(1). 65–71. 22 indexed citations

Hetland, Thea Eline, Dag André Nymoen, Arild Holth, et al.. (2012). Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. Human Pathology. 44(5). 777–785. 19 indexed citations

Paulsen, Torbjørn, Anne Hansen Ree, J. Kærn, et al.. (2007). Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation.. PubMed. 28(5). 356–63. 3 indexed citations

Hoei‐Hansen, Christina Engel, Sigrid Marie Kraggerud, Vera M. Abeler, et al.. (2007). Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers.. Molecular Cancer. 6(1). 12–12. 101 indexed citations

Tropé, Claes G. & J. Kærn. (2006). Primary surgery for ovarian cancer. European Journal of Surgical Oncology. 32(8). 844–852. 23 indexed citations

Paulsen, Torbjørn, Kristina Kjærheim, J. Kærn, Steinar Tretli, & Claes G. Tropé. (2006). Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. International Journal of Gynecological Cancer. 16(S1). 11–17. 126 indexed citations

Aghmesheh, Morteza, Michael Friedländer, Jahn M. Nesland, et al.. (2006). Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas. Pathology. 38(2). 145–151. 2 indexed citations

Kristensen, Gunnar B., Ignace Vergote, Gavin Stuart, et al.. (2005). First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival. International Journal of Gynecological Cancer. 15(s3). 221–221. 6 indexed citations

10.

Paulsen, Torbjørn, J. Kærn, Kristina Kjærheim, C. Tropé, & Steinar Tretli. (2004). Symptoms and referral of women with epithelial ovarian tumors. International Journal of Gynecology & Obstetrics. 88(1). 31–37. 18 indexed citations

11.

Kildal, Wanja, J. Kærn, Sigrid Marie Kraggerud, et al.. (2004). Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors—relation to clinicopathologic variables. Cancer Genetics and Cytogenetics. 155(1). 25–32. 10 indexed citations

12.

Kristensen, Gunnar B., Wanja Kildal, Vera M. Abeler, et al.. (2003). Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Annals of Oncology. 14(10). 1494–1500. 53 indexed citations

13.

Vergote, Ignace, et al.. (2002). First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel-epirubicin-carboplatin (TEC) vs paclitaxel-carboplatin (TC). Interim results of an NSGO-EORTC GCG - NCIC CTG intergroup Phase III study. International Journal of Gynecological Cancer. 12(5). 4 indexed citations

14.

Tropé, Claes G., et al.. (2001). Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer.. PubMed. 22(3). 223–7. 2 indexed citations

15.

Kristensen, Gunnar B., Wanja Kildal, Renate Pettersen, et al.. (2000). High-resolution Image Analysis - A Better Method for Predicting Prognosis in Early Ovarian Cancer. Gynecologic Oncology. 76(2). 236–236. 2 indexed citations

16.

Paulsen, Torbjørn, J. Kærn, & Claes G. Tropé. (1998). Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.. PubMed. 19(6). 524–8. 1 indexed citations

17.

Tropé, Claes G., J. Kærn, Gunnar B. Kristensen, P. Rosenberg, & Bengt Sorbe. (1997). Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer. Annals of Oncology. 8(8). 803–806. 9 indexed citations

18.

Vergote, Ignace, et al.. (1993). Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. American Journal of Obstetrics and Gynecology. 169(1). 40–52. 93 indexed citations

19.

Helland, Åslaug, R Holm, J. Kærn, et al.. (1992). TP53 mutation and HPV-infection in primary cervical carcinomas. Cancer Genetics and Cytogenetics. 63(2). 116–116. 2 indexed citations

20.

Kærn, J., et al.. (1990). Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecologic Oncology. 38(3). 452–457. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact